Zenas BioPharma completes IPO; adopts restated charter and amended bylaws

Zenas BioPharma, Inc.

Authorized 175M shares of common stock and 25M shares of undesignated preferred stock.
Eliminated stockholder ability to act by written consent and removed prior preferred series references.
Amended bylaws establish procedures for stockholder proposals and director nominations.
Charter and bylaws became effective upon IPO consummation on September 16, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.